The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
The clinical and functional significance of c-Met in breast cancer: a review
Open accessAbstract
c-Met is a receptor tyrosine kinase that upon binding of its ligand, hepatocyte growth factor (HGF), activates downstream pathways with diverse cellular functions that are important in organ development and cancer progression. Anomalous c-Met signalling has been described in a variety of cancer types, and the receptor is regarded as a novel therapeutic target. In breast cancer there is a need to develop new treatments, particularly for the aggressive subtypes such as triple-negative and basal-like cancer, which currently lack targeted therapy. Over the last two decades, much has been learnt about the functional role of c-Met signalling in different models of breast development and cancer. This work has been complemented by clinical studies, establishing the prognostic significance of c-Met in tissue samples of breast cancer. While the clinical trials of anti-c-Met therapy in advanced breast cancer progress, there is a need to review the existing evidence so that the potential of these treatments can be better appreciated. The aim of this article is to examine the role of HGF/c-Met signalling in in vitro and in vivo models of breast cancer, to describe the mechanisms of aberrant c-Met signalling in human tissues, and to give a brief overview of the anti-c-Met therapies currently being evaluated in breast cancer patients. We will show that the HGF/c-Met pathway is associated with breast cancer progression and suggest that there is a firm basis for continued development of anti-c-Met treatment, particularly for patients with basal-like and triple-negative breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
Shattuck, D. L., Miller, J. K., Carraway, K. L., & Sweeney, C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5962 · Cited by 473
Qian, F., Engst, S., Yamaguchi, K., Yu, P., Won, K.-A., Mock, L., Lou, T., Tan, J., Li, C., Tam, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4889 · Cited by 350 · cited 2×
“Foretinib inhibits HGF-induced c-Met phosphorylation, inhibits tumour cell growth in hypoxic and normoxic conditions, and has been shown to reduce tumour cell burden in an in vivo model of lung cancer [92].”
BackgroundWang, X., DeFrances, M. C., Dai, Y., Pediaditakis, P., Johnson, C., Bell, A., Michalopoulos, G. K., & Zarnegar, R. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00439-2 · Cited by 225 · cited 3×
“Such a model would explain the paradoxical effects of HGF/c-Met on cell survival [71].”
BackgroundInfluentialEdakuni, G., Sasatomi, E., Satoh, T., Tokunaga, O., & Miyazaki, K. (2001) · Pathology International · doi:10.1046/j.1440-1827.2001.01182.x · Cited by 130
Hiscox, S., & Jiang, W. G. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1002 · Cited by 126
Fibroblast Hepatocyte Growth Factor Promotes Invasion of Human Mammary Ductal Carcinoma In situ
Jedeszko, C., Victor, B. C., Podgorski, I., & Sloane, B. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1043 · Cited by 104 · cited 4×
“Administration of HGF, either in the form of recombinant HGF, conditioned media from HGF-secreting fibroblasts or by way of co-culture with HGF-secreting fibroblasts, has been shown to significantly increase migration and invasion in wound closure and transwell invasion assays [59-62].”
BackgroundInfluential
Cited by
E-cadherin in contact inhibition and cancer
Mendonsa, A. M., Na, T.-Y., & Gumbiner, B. M. (2018) · Oncogene · doi:10.1038/s41388-018-0304-2 · Cited by 526
Tchou, J., Zhao, Y., Levine, B. L., Zhang, P. J., Davis, M. M., Melenhorst, J. J., Kulikovskaya, I., Brennan, A. L., Liu, X., Lacey, S. F., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0189 · Cited by 452
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, J. L., & Hung, M.-C. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 445
Contribution of adipose tissue to development of cancer
Cozzo, A. J., Fuller, A. M., & Makowski, L. (2017) · Comprehensive Physiology · doi:10.1002/cphy.c170008 · Cited by 188
Immunotherapy in breast cancer: Current status and future directions
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2019.03.006 · Cited by 109
Metadata
- Authors
- Ho-Yen, C. M., Jones, J. L., & Kermorgant, S.
- Venue
- Breast Cancer Research
- Published
- 2015-04-08
- Volume
- 17
- Issue
- 1
- Pages
- 52-52
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W2104013286
- Cited by
- 197
- References
- 7
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The clinical and functional significance of c-Met in breast cancer: a review. https://app.cochat.ai/papers/10.1186/s13058-015-0547-6
- The paper
- Ho-Yen, C. M., Jones, J. L., & Kermorgant, S. (2015). The clinical and functional significance of c-Met in breast cancer: a review. Breast Cancer Research. https://doi.org/10.1186/s13058-015-0547-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.